NO332405B1 - Compound of 5-substituted quinoline and isoquinoline derivatives, process for their preparation, their use in the preparation of pharmaceutical agents for the treatment of inflammatory disease and pharmaceutical composition comprising the compound. - Google Patents

Compound of 5-substituted quinoline and isoquinoline derivatives, process for their preparation, their use in the preparation of pharmaceutical agents for the treatment of inflammatory disease and pharmaceutical composition comprising the compound.

Info

Publication number
NO332405B1
NO332405B1 NO20072963A NO20072963A NO332405B1 NO 332405 B1 NO332405 B1 NO 332405B1 NO 20072963 A NO20072963 A NO 20072963A NO 20072963 A NO20072963 A NO 20072963A NO 332405 B1 NO332405 B1 NO 332405B1
Authority
NO
Norway
Prior art keywords
compound
preparation
treatment
inflammatory disease
pharmaceutical composition
Prior art date
Application number
NO20072963A
Other languages
Norwegian (no)
Other versions
NO20072963L (en
Inventor
Werner Skuballa
Orlin Petrov
Heike Schacke
Matthias Schneider
Hartmut Rehwinkel
Norbert Schmees
Stefan Jaroch
Jan Huebner
Christian Dinter
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102005020331A external-priority patent/DE102005020331A1/en
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of NO20072963L publication Critical patent/NO20072963L/en
Publication of NO332405B1 publication Critical patent/NO332405B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
NO20072963A 2004-11-12 2007-06-11 Compound of 5-substituted quinoline and isoquinoline derivatives, process for their preparation, their use in the preparation of pharmaceutical agents for the treatment of inflammatory disease and pharmaceutical composition comprising the compound. NO332405B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004055633A DE102004055633A1 (en) 2004-11-12 2004-11-12 New 5-substituted quinoline and isoquinoline derivatives are glucocorticoid receptor binders useful for treating inflammatory diseases e.g. alveolitis, Sjogren's syndrome, atopic dermatitis, acute lymphatic leukemia, rhinitis and emesis
DE102005020331A DE102005020331A1 (en) 2005-04-26 2005-04-26 New 5-substituted quinoline and isoquinoline derivatives are glucocorticoid receptor binders useful for treating inflammatory diseases e.g. alveolitis, Sjogren's syndrome, atopic dermatitis, acute lymphatic leukemia, rhinitis and emesis
PCT/EP2005/012531 WO2006050998A1 (en) 2004-11-12 2005-11-11 5-substituted quinoline and isoquinoline derivatives, a method for the production thereof and their use as antiphlogistics

Publications (2)

Publication Number Publication Date
NO20072963L NO20072963L (en) 2007-08-03
NO332405B1 true NO332405B1 (en) 2012-09-10

Family

ID=35613753

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072963A NO332405B1 (en) 2004-11-12 2007-06-11 Compound of 5-substituted quinoline and isoquinoline derivatives, process for their preparation, their use in the preparation of pharmaceutical agents for the treatment of inflammatory disease and pharmaceutical composition comprising the compound.

Country Status (31)

Country Link
EP (1) EP1844039B1 (en)
JP (1) JP4460608B2 (en)
KR (1) KR101168462B1 (en)
CN (1) CN101124220B (en)
AR (1) AR051767A1 (en)
AU (1) AU2005303926B2 (en)
BR (1) BRPI0517797A (en)
CA (1) CA2586689C (en)
CY (1) CY1110520T1 (en)
DE (2) DE102004055633A1 (en)
DK (1) DK1844039T3 (en)
EA (1) EA013076B1 (en)
ES (1) ES2329599T3 (en)
GT (1) GT200500330A (en)
HK (1) HK1112243A1 (en)
HR (1) HRP20090509T1 (en)
IL (1) IL182933A (en)
ME (2) MEP13608A (en)
MX (1) MX2007005736A (en)
MY (1) MY141780A (en)
NO (1) NO332405B1 (en)
NZ (1) NZ555064A (en)
PA (1) PA8652701A1 (en)
PE (1) PE20061052A1 (en)
PL (1) PL1844039T3 (en)
PT (1) PT1844039E (en)
RS (2) RS20070205A (en)
SI (1) SI1844039T1 (en)
TW (1) TWI311559B (en)
UY (1) UY29213A1 (en)
WO (1) WO2006050998A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
TWI464148B (en) 2006-03-16 2014-12-11 Evotec Us Inc Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
EP2051736A2 (en) * 2006-07-07 2009-04-29 Bausch & Lomb Incorporated Compositions comprising a dissociated glucocorticoid receptor agonist and an immunosuppressive agent for treating dry eye
ES2403512T3 (en) 2006-08-07 2013-05-20 Bausch & Lomb Incorporated Compositions and methods to treat, control, reduce, or improve infections and their sequelae
KR20090051076A (en) * 2006-08-07 2009-05-20 보오슈 앤드 롬 인코포레이팃드 Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases
CN101528208A (en) * 2006-08-31 2009-09-09 博士伦公司 Compositions and methods for treating or preventing glaucoma or progression thereof
US20110104159A1 (en) * 2006-09-11 2011-05-05 Rohrs Brian R Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy
US20110105559A1 (en) * 2006-09-11 2011-05-05 Rohrs Brian R Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy
MX2009002544A (en) * 2006-09-11 2009-03-20 Bausch & Lomb Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy.
JP2010509347A (en) * 2006-11-09 2010-03-25 ボーシュ アンド ローム インコーポレイティド Selective synthesis of stereoisomers of certain substituted alcohols.
CN101679247B (en) * 2007-04-18 2014-02-19 茵坦蒂斯股份有限公司 Process for the manufacture for non-steroidal anti-inflammatory agents and intermediates thereof
EP1982976A1 (en) * 2007-04-18 2008-10-22 Intendis GmbH Process for the manufacture of non-steroidal anti-inflammatory agents and intermediates thereof
EP2016935A1 (en) * 2007-07-09 2009-01-21 Intendis GmbH Pharmaceutical composition for topical application of poorly soluble compounds
US20090042936A1 (en) * 2007-08-10 2009-02-12 Ward Keith W Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation
US20090087443A1 (en) * 2007-09-27 2009-04-02 Bartels Stephen P Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery
KR20100072333A (en) * 2007-11-01 2010-06-30 보오슈 앤드 롬 인코포레이팃드 Non-aqueous water-miscible materials as vehicles for drug delivery
US20110077270A1 (en) * 2009-04-21 2011-03-31 Pfeffer Bruce A Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
CN101983961B (en) * 2010-11-24 2012-05-09 浙江启明生化科技有限公司 Preparation method of 5-amino-2-methyl quinoline
US20120316199A1 (en) 2011-06-07 2012-12-13 Ward Keith W Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain
WO2017137375A1 (en) 2016-02-12 2017-08-17 Bayer Animal Health Gmbh Mapracorat for use in the treatment of canine dermatitis
CN111732493B (en) * 2017-01-16 2023-01-24 宜昌尚诺德生物医药科技有限公司 Synthesis process of arylamine compound
AU2020211303A1 (en) 2019-01-22 2021-07-15 Akribes Biomedical Gmbh Selective Glucocorticoid Receptor Modifiers for treating impaired skin wound healing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4041482A1 (en) * 1990-12-22 1992-06-25 Boehringer Ingelheim Kg NEW PHARMACEUTICAL USE OF CARBOCYCLIC AND HETEROCYCLICALLY ANNELATED DIHYDROPYRIDINE
NO306992B1 (en) * 1993-01-28 2000-01-24 Takeda Chemical Industries Ltd Quinoline derivatives, pharmaceutical preparations containing the compounds and the use of the compounds
RU2127271C1 (en) * 1997-03-13 1999-03-10 Пермская государственная фармацевтическая академия 2-chloro-5,6,7,8-tetrahydroquinoline-4-carboxylic acid 5-nitrofurfurylidene hydrazide eliciting an antibacterial activity
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
DE10215316C1 (en) * 2002-04-02 2003-12-18 Schering Ag Quinoline and isoquinoline derivatives, a pharmaceutical agent and their use as anti-inflammatory agents
AU2003297471A1 (en) * 2003-01-03 2004-08-10 Boehringer Ingelheim Pharmaceuticals, Inc. 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands
US20040224992A1 (en) * 2003-02-27 2004-11-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7179919B2 (en) * 2004-03-18 2007-02-20 Boehringer Ingelheim Pharmaceuticals, Inc. Stereoselective synthesis of certain trifluoromethyl-substituted alcohols

Also Published As

Publication number Publication date
AU2005303926B2 (en) 2011-05-19
SI1844039T1 (en) 2009-12-31
ES2329599T3 (en) 2009-11-27
UY29213A1 (en) 2006-05-31
DE102004055633A1 (en) 2006-05-18
EA200700982A1 (en) 2007-10-26
NZ555064A (en) 2009-09-25
AU2005303926A1 (en) 2006-05-18
HK1112243A1 (en) 2008-08-29
ME00155B (en) 2010-10-10
JP4460608B2 (en) 2010-05-12
DE502005007725D1 (en) 2009-08-27
PT1844039E (en) 2009-10-19
TWI311559B (en) 2009-07-01
EA013076B1 (en) 2010-02-26
KR101168462B1 (en) 2012-07-27
RS51161B (en) 2010-10-31
HRP20090509T1 (en) 2009-11-30
JP2008519803A (en) 2008-06-12
DK1844039T3 (en) 2009-11-09
CA2586689C (en) 2012-04-17
RS20070205A (en) 2008-11-28
TW200640913A (en) 2006-12-01
WO2006050998A1 (en) 2006-05-18
MX2007005736A (en) 2007-09-07
PA8652701A1 (en) 2006-07-03
GT200500330A (en) 2006-09-21
MEP13608A (en) 2010-06-10
AR051767A1 (en) 2007-02-07
BRPI0517797A (en) 2008-10-21
CY1110520T1 (en) 2015-04-29
PL1844039T3 (en) 2009-12-31
CN101124220B (en) 2012-04-25
IL182933A (en) 2011-10-31
NO20072963L (en) 2007-08-03
KR20070084192A (en) 2007-08-24
EP1844039B1 (en) 2009-07-15
MY141780A (en) 2010-06-30
CA2586689A1 (en) 2006-05-18
PE20061052A1 (en) 2006-11-08
IL182933A0 (en) 2007-09-20
EP1844039A1 (en) 2007-10-17
CN101124220A (en) 2008-02-13

Similar Documents

Publication Publication Date Title
NO332405B1 (en) Compound of 5-substituted quinoline and isoquinoline derivatives, process for their preparation, their use in the preparation of pharmaceutical agents for the treatment of inflammatory disease and pharmaceutical composition comprising the compound.
NO340679B1 (en) Pyridazine derivatives, pharmaceutical compositions comprising such and such compounds and preparations for use in therapeutically active substances for the treatment and prevention of diseases
DK1761266T3 (en) Compounds, Formulations and Methods for Treating or Preventing Inflammatory Skin Diseases
NO20053245D0 (en) Tablets with modified release of bupropion hydrochloride.
DK1620429T3 (en) New heterocyclic compounds useful in the treatment of inflammatory and allergic diseases, methods of their preparation and pharmaceutical compositions containing them
DK1981889T3 (en) CYTOTOXIC AGENTS INCLUDING NEW TOMAYMYCIN DERIVATIVES AND THERAPEUTIC APPLICATION THEREOF
NO20055686L (en) Composition, method of preparation thereof, and use thereof.
DK1853271T3 (en) Method and Preparation for the Treatment of Peripheral Vascular Diseases
BRPI0508263B8 (en) 1, 2, 3,4-tetrahydro-isoquinoline derivatives, pharmaceutical composition, and use of 1, 2, 3,4-tetrahydro-isoquinoline derivative
IL193467A0 (en) Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
NO20070753L (en) Process for the preparation of dihydropteridinones
CL2007003265A1 (en) COMPOUNDS DERIVED FROM 1H-PIRAN [2,3-D] PIRIMIDIN-2,4,7-TRIONA; AND PHARMACEUTICAL COMPOSITION, USEFUL FOR THE TREATMENT OF METABOLIC SYNDROME, DYSLIPIDEMIA AND CARDIOVASCULAR DISEASES BETWEEN OTHERS.
MA28489B1 (en) PHARMACEUTICAL PREPARATIONS
DK2069342T3 (en) Derivatives of 2-aryl-6-phenyl-imidazole [1,2-A] pyridines, preparation and therapeutic use thereof
HK1126119A1 (en) Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3- propanaediol derivative as active ingredient, and its use in manufacture of medicines for preventing or treating inflammatory bowel disease 2--13-
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
DK1939204T3 (en) Condensed heterocyclic derivative, pharmaceutical composition containing the same and medical use thereof
DK1922309T3 (en) N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCEDURE FOR THE PREPARATION OF THEREOF
NO20052262D0 (en) Process for Preparation of 4-Substituted 2,2,6,6-Tetramethyl-Piperidine-N-Oxy and 2,2,6,6-Tetramethyl-Piperidine-N-Hydroxy Compounds
NL1025073C2 (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use.
CL2007003690A1 (en) COMPOUNDS DERIVED FROM 1-AZONIA-BICICLO [2.2.2] OCTANO; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES.
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
AP2413A (en) 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other disease.
NO20053348D0 (en) Pharmaceutical composition for the treatment of viral attacks.
CL2007003038A1 (en) COMPOUNDS DERIVED FROM 2-PHENYL-6-AMINOCARBONIL-PYRIMIDINE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees